Cargando…

Small Airways Disease, Biomarkers and COPD: Where are We?

The response to treatment and progression of Chronic Obstructive Pulmonary Disease (COPD) varies significantly. Small airways disease (SAD) is being increasingly recognized as a key pathological feature of COPD. Studies have brought forward pathological evidence of small airway damage preceding the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chukowry, Priyamvada S, Spittle, Daniella A, Turner, Alice M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899307/ https://www.ncbi.nlm.nih.gov/pubmed/33628018 http://dx.doi.org/10.2147/COPD.S280157

Ejemplares similares

A Systematic Review and Meta-analysis of the Prevalence and Impact of Pulmonary Bacterial Colonisation in Stable State Chronic Obstructive Pulmonary Disease (COPD)
por: Armitage, Michael N., et al.
Publicado: (2021)

Personalized medicine for patients with COPD: where are we?
por: Franssen, Frits ME, et al.
Publicado: (2019)

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going
por: Boscarino, Giovanni, et al.
Publicado: (2023)

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?
por: Zhao, Xiao-Su, et al.
Publicado: (2019)

Precision medicine in COPD: where are we and where do we need to go?
por: Sidhaye, Venkataramana K., et al.
Publicado: (2018)

Geroprotectors as a therapeutic strategy for COPD – where are we now?
por: Miłkowska-Dymanowska, Joanna, et al.
Publicado: (2017)

Biomarkers for renal transplantation: where are we?
por: Ge, Fangmin, et al.
Publicado: (2013)

Inflammation and Immune Response in COPD: Where Do We Stand?
por: Rovina, Nikoletta, et al.
Publicado: (2013)

Chronic Obstructive Airways Diseases: Where Are We Now?
por: Minov, Jordan, et al.
Publicado: (2015)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Predicting Lung Function Using Biomarkers in Alpha-1 Antitrypsin Deficiency
por: Spittle, Daniella A., et al.
Publicado: (2023)

Osteoarthritis and Diabetes: Where Are We and Where Should We Go?
por: Alenazi, Aqeel M., et al.
Publicado: (2023)

Current Status for Gastrointestinal Nematode Diagnosis in Small Ruminants: Where Are We and Where Are We Going?
por: Preston, Sarah Jane Margaret, et al.
Publicado: (2014)

Colorectal Cancer Biomarkers: Where Are We Now?
por: Gonzalez-Pons, Maria, et al.
Publicado: (2015)

EEG Recordings as Biomarkers of Pain Perception: Where Do We Stand and Where to Go?
por: Zis, Panagiotis, et al.
Publicado: (2022)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Animal Sentience: Where are We and Where are We Heading?
por: Proctor, Helen
Publicado: (2012)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

The pathology of small airways disease in COPD: historical aspects and future directions
por: Higham, Andrew, et al.
Publicado: (2019)

Treatment of upper airway resistance syndrome in adults: Where do we stand?()
por: de Godoy, Luciana B.M., et al.
Publicado: (2015)

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
por: Hasenoehrl, Carina, et al.
Publicado: (2017)

Host Diagnostic Biomarkers of Infection in the ICU: Where Are We and Where Are We Going?
por: Heffernan, Aaron J., et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Dysfunctional lung anatomy and small airways degeneration in COPD
por: Martin, Clémence, et al.
Publicado: (2013)

Highlights and hot topics in the management of COPD: where are we heading?
por: Agustí, Alvar, et al.
Publicado: (2016)

MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
por: Cuttano, Roberto, et al.
Publicado: (2022)

Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
por: Cova, Ilaria, et al.
Publicado: (2018)

A systematic review of interventions aiming to improve newly-qualified doctors’ wellbeing in the United Kingdom
por: Krishnan, Aditya, et al.
Publicado: (2022)

Hepatitis C Vaccination: Where We Are and Where We Need to Be
por: Manne, Vignan, et al.
Publicado: (2021)

Colon Capsule Endoscopy: Where Are We and Where Are We Going
por: Han, Yoo Min, et al.
Publicado: (2016)

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
por: Hayes, Gemma E., et al.
Publicado: (2016)

Accommodative intraocular lenses: where are we and where we are going
por: Alió, Jorge L., et al.
Publicado: (2017)

Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now?
por: San Francisco, Ignacio F., et al.
Publicado: (2023)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Male contraception: where are we going and where have we been?
por: Reynolds-Wright, John Joseph, et al.
Publicado: (2019)

Research Integrity: Where We Are and Where We Are Heading
por: Zhaksylyk, Alikhan, et al.
Publicado: (2023)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022)

Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?
por: Mourtzi, Theodora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_verch40b8poa3jg8t8gq1u8rti